Chemoembolization and Interstitial Therapies for Hepatocellular Carcinoma

  • D. Michael Rose
  • William C. Chapman
Part of the Cancer Treatment and Research book series (CTAR, volume 109)


Hepatocellular carcinoma (HCC) remains one of the most common malignancies worldwide, causing approximately 1,250,000 deaths annually (1). In the United States, HCC accounts for 1% of all new cancer diagnoses and 2% of all cancer deaths (2). According to data collected by the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, HCC survival rates in this country are dismal with an overall five-year survival of 3%. Patients with localized disease had an 8% five-year survival compared to 2% in patients with either regional or distant disease (2). Surgical resection is the preferred treatment for HCC; unfortunately, only 20% of all patients with HCC are suitable candidates for resection (3,4). Of those who undergo resection, approximately 30–70% will have a hepatic recurrence (3–5). With the preponderance of patients not eligible for surgical intervention, multiple alternative approaches have been developed including hepatic-directed therapies (transcatheter arterial chemoembolization, hepatic artery ligation) and local tumor ablation (percutaneous ethanol injection, cryosurgical ablation, interstitial laser photocoagulation, microwave tumor coagulation, radiofrequency ablation). This chapter will examine the rationale and results with two of these modalities: transcatheter chemoembolization and percutaneous ethanol injection.


Hepatocellular Carcinoma Percutaneous Ethanol Injection Transcatheter Arterial Chemoembolization Hepatic Artery Ligation Interstitial Laser Photocoagulation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Venook AP. Treatment of hepatocellular carcinoma: too many options? J Clin Oncol, 1994;12(6):1323.PubMedGoogle Scholar
  2. 2.
    Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer, 1995;75(1 Suppl):171.PubMedCrossRefGoogle Scholar
  3. 3.
    Liu C-L, Fan S-T. Nonresectional therapies for hepatocellular carcinoma. Am J Surg, 1997;173:358.PubMedCrossRefGoogle Scholar
  4. 4.
    Farmer DG, Rosove MH, Shaked A, Busuttil RW. Current treatment modalities for haepatocellular carcinoma. Ann Surg, 1994;219(3):236.PubMedCrossRefGoogle Scholar
  5. 5.
    Bruix J. Treatment of hepatocellular carcinoma. Hepatology, 1997;25(2):259.PubMedCrossRefGoogle Scholar
  6. 6.
    Trinchet J-C, Beaugrand M. Treatment of hepatocellular carcinoma in patients with cirrhosis. J Hepatol, 1997;27:756.PubMedCrossRefGoogle Scholar
  7. 7.
    Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.. J Hepatol 1990,11:181.CrossRefGoogle Scholar
  8. 8.
    Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N EnglJ Med, 1995;332(19):1256.CrossRefGoogle Scholar
  9. 9.
    Vetter D, Wenger JJ, Bergier JM, et al. Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a western comparative study in 60 patients. Hepatology, 1991; 13(3):427.PubMedCrossRefGoogle Scholar
  10. 10.
    Bronowicki JP, Vetter D, Dumas F, et al.. Transcatheter oily chemoembolization for hepatocellular carcinoma: a 4-year study of 127 patients. Carter, 1994;74(1):16.Google Scholar
  11. 11.
    Stefanini GF, Amorati P, Biselli M, et al.. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma: an italian experience. Cancer, 1995; 75(10):2427.Google Scholar
  12. 12.
    Bronowicki J-P, Boudjema K, Chone L, et al. Comparison of resection, liver transplantation and transcatheter oily chemoembolization in the treatment of hepatocellular carcinoma. J Hepatol, 1996;24:293.PubMedCrossRefGoogle Scholar
  13. 13.
    Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the united states: prognostic features, treatment outcome, and survival. Cancer, 1996;77(11):2217.Google Scholar
  14. 14.
    Marcos-Alvarez A, Jenkins RL, Washburn WK, et al. Multimodality treatment of hepatocellular carcinoma in a hepatobiliary specialty center. Arch Surg, 1996; 131:292.PubMedCrossRefGoogle Scholar
  15. 15.
    Ryder SD, Rizzi PM, Metivier E, et al. Chemoembolisation with lipiodol and doxorubicin: applicability in british patients with hepatocellular carcinoma. Gut, 1996; 38:125.PubMedCrossRefGoogle Scholar
  16. 16.
    Rose DM, Pinson CW, Brokenbrough AT, et al. Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma. Am J Surg (in press).Google Scholar
  17. 17.
    Lehnert T, Herfarth C. Chemoembolization for hepatocellular carcinoma: what, when, and for whom? Ann Surg, 1996;224(1): 1.PubMedCrossRefGoogle Scholar
  18. 18.
    Raoul J-L, Guyader D, Bretagne J-F, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 13-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology, 1997;26(5):1156.PubMedGoogle Scholar
  19. 19.
    Cohen SE, Safadi R, Verstandig A, et al. Liver-spleen infarcts following transcatheter chemoembolization: a case report and review of the literature on adverse effects. Dig Dis Sei, 1997;42(5):938.CrossRefGoogle Scholar
  20. 20.
    Bismuth H, Morino M, Sherlock D, et al. Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg, 1992;163:387.PubMedCrossRefGoogle Scholar
  21. 21.
    Berger DH, Carrasco CH, Hohn DC, Curley SA. Hepatic artery chemoembolization or embolization for primary and metastatic liver tumors: post-treatment management and complications. J Surg Oncol, 1995;60:116.PubMedCrossRefGoogle Scholar
  22. 22.
    Lopez RR, Pan S, Lois JF, et al. Transarterial chemoembolization is a safe treatment for unresectable hepatic malignancies. Am Surg, 1997;63:923.PubMedGoogle Scholar
  23. 23.
    Lee H-S, Kim JS, Choi I J, et al. The safety and eficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. Cancer, 1997; 79(11): 2087.Google Scholar
  24. 24.
    Okuda K, Obata H, Ohtsuki T, et al. Prognosis of primary hepatocellular carcinoma. Hepatology, 1984;4(1):3S.CrossRefGoogle Scholar
  25. 25.
    Farinati F, De Maria N, Marafin C, et al. Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization. Dig Dis Sei, 1996;41(12):2332.Google Scholar
  26. 26.
    Mondazzi L, Bottelli R, Brambilla G, et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology, 1994;19(5):1115.PubMedCrossRefGoogle Scholar
  27. 27.
    Lu C-D, Peng S-Y, Jiang X-C, Chiba Y, Tanigawa N. Preoperative transcatheter arterial chemoembolization and prognosis of patients with hepatocellular carcinoma: retrospective analysis of 120 cases. World J Surg, 1999; 23: 293.PubMedCrossRefGoogle Scholar
  28. 28.
    Majno PE, Adam R, Bismuth H, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg, 1997; 226(6): 688.PubMedCrossRefGoogle Scholar
  29. 29.
    Harada T, Matsuo K, Inoue T, et al. Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma? Ann Surg, 1996;224(1):4.PubMedCrossRefGoogle Scholar
  30. 30.
    Sugiura N, Takara K, Ohto M, Okuda K, Hirooka N. Percutaneous intratumoral injection of ethanol under ultrasound imaging for treatment of small hepatocellular carcinoma. Acta Hepatol Jpn, 1983; 24: 920.Google Scholar
  31. 31.
    De Sanctis JT, Goldberg SN, Mueller PR. Percutaneous treatment of hepatic neoplasms: a review of current techniques. Cardiovasc Intervent Radiol, 1998; 21: 273.PubMedCrossRefGoogle Scholar
  32. 32.
    Lee MJ, Mueller PR, Dawson SL, et al. Percutaneous ethanol injection for the treatment of hepatic tumors: indications, mechanism of action, technique and efficacy. Am J Radiol, 1995; 164: 215.Google Scholar
  33. 33.
    Livraghi T. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. Hepato-gastroenterol, 1998; 45: 1248.Google Scholar
  34. 34.
    Livraghi T, Lazzaroni S, Pellicano S, et al. Percutaneous ethanol injection of hepatic tumors: single-session therapy with general anesthesia. Am J Radiol, 1993; 161: 1065.Google Scholar
  35. 35.
    Livraghi T, Bolondi L, Buscarini L, et al. No treatment, resection, and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. J Hepatol, 1995; 22:522.CrossRefGoogle Scholar
  36. 36.
    Castells A, Bruix J, Bru C, et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology, 1993; 18: 1121.PubMedGoogle Scholar
  37. 37.
    Okuda K. Intratumoral ethanol injection. J Surg Oncol Suppl, 1993; 3:97.PubMedCrossRefGoogle Scholar
  38. 38.
    Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology, 1995; 197(1): 101.PubMedGoogle Scholar
  39. 39.
    Lencioni R, Cioni D, Uliana M, Bartolozzi C. Fatal thrombosis of the portal vein following single-session percutaneous injection therapy of hepatocellular carcinoma. Abdom Imaging, 1998; 23: 608.PubMedCrossRefGoogle Scholar
  40. 40.
    Tapani E, Soiva M, Lavonen J, Ristkari S, Vehmas T. Complications following high-dose percutaneous ethanol injection into hepatic tumors. Acta Radiologica, 1996; 37: 655.PubMedCrossRefGoogle Scholar
  41. 41.
    Shimada M, Maeda T, Saitoh A, Morotomi I, Kano T. Needle track seeding after percutaneous ethanol injection therapy for small hepatocellular carcinoma. J Surg Oncol, 1995; 58: 278.PubMedCrossRefGoogle Scholar
  42. 42.
    Sammack B, Yousef B, Abd El Bagi M, et al. Needle track seeding following percutaneous ethanol injection for treatment of hepatocellular carcinoma. Hepato-gastroenterol, 1998; 45: 1097.Google Scholar
  43. 43.
    Ishii H, Okada S, Okusaka T, et al. Needle tract implantation of hepatocellular carcinoma after percutaneous ethanol injection. Cancer, 1998; 82: 1638.PubMedCrossRefGoogle Scholar
  44. 44.
    Lencioni R, Caramella D, Bartolozzi C. Hepatocellular carcinoma: use of color doppler US to evaluate response to treatment with percutaneous ethanol injection. Radiology, 1995; 194: 113.PubMedGoogle Scholar
  45. 45.
    Ishii H, Okada S, Nose H, et al. Predictive factors for recurrence after percutaneous ethanol injection for solitary hepatocellular carcinoma. Hepato-gastroenterol, 1996; 43: 938.Google Scholar
  46. 46.
    Ishii H, Okada S, Nose H, et al. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer, 1996; 77: 1792.PubMedCrossRefGoogle Scholar
  47. 47.
    Lencioni R, Paolicchi A, Moretti M, et al. Combined transcatheter arterial chemoembolization and percutaneous ethanol injection for the treatment of large hepatocellular carcinoma: local therapeutic effect and long-term survival rate. Eur Radiol, 1998; 8: 439.PubMedCrossRefGoogle Scholar
  48. 48.
    Tanaka K, Nakamura S, Numata K, et al. The long term efficacy of combined transcatheter arterial embolization and percutaneous ethanol injection in the treatment of patients with large hepatocellular carcinoma and cirrhosis. Cancer, 1998; 82: 78.PubMedCrossRefGoogle Scholar
  49. 49.
    Yamamoto K, Masuzawa M, Kato M, et al. Evaluation of combined therapy with chemoembolization and ethanol injection for advanced hepatocellular carcinoma. Semin Oncol Suppl, 1997; 24(2): S6–50.Google Scholar
  50. 50.
    Tateishi H, Kinuta M, Furukawa J, et al. Follow-up study of combined treatment (TAE and PEIT) for unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol Suppl, 1994; 33: S 119.CrossRefGoogle Scholar
  51. 51.
    Bartolozzi C, Lencioni R, Caramella D, et al. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology, 1995; 197: 812.PubMedGoogle Scholar
  52. 52.
    Allgaier H-P, Deibert P, Olschewski M, et al. Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection - a single-center analysis including 132 patients. Int J Cancer, 1998; 79: 601.PubMedCrossRefGoogle Scholar
  53. 53.
    Sato M, Watanabe Y, Iseki N, et al. Chemoembolization and percutaneous ethanol injection for intrahepatic recurrence of hepatocellular carcinoma after hepatic resection. Hepato-Gastroenterol, 1996; 43: 1421.Google Scholar
  54. 54.
    Ishii H, Okada S, Sato T, et al. Effect of percutaneous ethanol injection for postoperative recurrence of hepatocellular carcinoma n combination with transcatheter arterial chemoembolization. Hepato-Gastroenterol, 1996; 43: 644.Google Scholar
  55. 55.
    Veltri A, Grosso M, Martina MC, et al. Effect of preoperative radiological treatment of hepatocellular carcinoma before liver transplantation: a retrospective study. Cardiovasc Intervent Radiol, 1998; 21: 393.PubMedCrossRefGoogle Scholar
  56. 56.
    Paulson EK. Ethanol injection of treatment of liver tumors. In: Malignant liver tumors: current and emerging therapies. Pierre-Alain Clavian (ed.); Blackwell Science, Maiden, Massachusetts, 1999: 181–188.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2001

Authors and Affiliations

  • D. Michael Rose
    • 1
  • William C. Chapman
    • 2
  1. 1.John Wayne Cancer InstituteSanta MonicaUSA
  2. 2.Vanderbilt University Medical CenterNashvilleUSA

Personalised recommendations